Compare Illumina, Inc. (ILMN) vs Oxford Lane Capital Corp (OXLC) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Illumina, Inc. vs Oxford Lane Capital Corp — how do they compare? Illumina, Inc. trades at $265.01 (market cap $39.95B), while Oxford Lane Capital Corp trades at $8.59 (market cap $835.71M). The key difference: Illumina, Inc. is far larger — about 47.8× Oxford Lane Capital Corp's market cap, and Oxford Lane Capital Corp pays a 28.15% dividend while Illumina, Inc. pays none. Which is the better fit depends on your goals — on Pluang, investors hold Illumina, Inc. for 83 Days and Oxford Lane Capital Corp for 49 Days on average.
| ILMN | OXLC | |
|---|---|---|
Market Cap | $39.95B | $835.71M |
Volume | 3,169,503 | 1,125,263 |
Sector | Health | Financials |
52-Week High | $293.69 | $16.74 |
52-Week Low | $91.00 | $8.15 |
Typical Hold Time | 83 Days | 49 Days |
Enterprise Value | $41.31B | $1.23B |
Dividend Yield | — | 28.15% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Illumina (ILMN) trades at $267.76, down 2.11% today but remains near recent highs after a strong 94.9% YTD rally. The stock shows bullish technical momentum with recent earnings beats and improved profitability, with net income turning positive to $850 million in 2025 after previous losses. S&P 500 inclusion in September 2026 and growing AI integration in genomics provide positive catalysts, though valuation metrics remain elevated with a P/E of 49.36.
Outlook remains positive with analyst consensus favoring Buy ratings (54%) and a $241 price target, though current price exceeds consensus. Key opportunities include sequencing growth and AI adoption, while risks include China headwinds, margin pressure, and high valuation multiples requiring sustained execution to justify premium pricing.
OXLC trades at $8.46, down 2.53% on the day, with a bearish technical outlook indicated by moving averages and oscillators. Recent earnings misses and a sharp decline in 2026 revenue and net income highlight fundamental challenges, though the stock trades below book value. The company maintains a regular dividend payout, but negative cash flow from operations and high interest expenses pose sustainability concerns.
The outlook is cautious due to deteriorating profitability and bearish sentiment, though deep valuation discounts may attract contrarian investors. Key risks include earnings volatility, dividend coverage, and market sentiment shifts. Analyst consensus is mixed, with half recommending buy but technicals signaling sell.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Illumina, Inc.
Illumina provides tools and services to analyze genetic material with life science and clinical lab applications. The company generates over 90% of its revenue from sequencing instruments, consumables, and services. Illumina's high-throughput technology enables whole genome sequencing in humans and other large organisms. Its lower throughput tools enable applications that require smaller data outputs, such as viral and cancer tumor screening. Illumina also sells microarrays (less than 10% of sales) that enable lower-cost, focused genetic screening with primarily consumer and agricultural applications.
Read more on ILMN →About Oxford Lane Capital Corp
Oxford Lane Capital Corp. is a non-diversified, closed-end management investment company. Its primary investment objective is to achieve high current income, with a secondary objective of capital appreciation. The company primarily invests in equity and junior debt tranches of collateralized loan obligations (CLOs), which are pools of corporate loans. OXLC is known for its high-yield distribution policy and provides investors with leveraged exposure to the CLO market.
Read more on OXLC →
